AIMS: To examine risks of sudden death in the community associated with drugs grouped by their risk of causing torsades de pointes (TdP) and to explore the risks for individual drugs. METHODS: Case-control study comparing prior drug intakes and morbidities, using the Arizona classification of drugs causing TdP. Participants included 1010 patients dying suddenly where post-mortem examination did not identify a clear cause of death, and 3030 matched living controls from primary care. RESULTS: Noncardiac drug risk was posed by antipsychotics and antidepressants. Significantly raised odds ratios (ORs) were found for takers of typical and atypical antipsychotics, ORs [95% confidence interval] 3.94 (2.05, 7.55) and 4.36 (2.54, 7.51), and of selective serotonin reuptake inhibitors [SSRIs] rather than tricyclic antidepressants, ORs 2.21 (1.61, 3.05) and 1.44 (0.96, 2.13). No significant risk was associated with other, noncardiac or psychiatric drugs, OR 1.09 (0.85, 1.41). Arizona classified drugs considered to raise risk of TdP were associated with raised risk of sudden death, as were those only weakly associated with TdP and not considered to pose a risk in normal use, ORs 2.08 (1.45, 3.00) and 1.74 (1.33, 2.28), respectively. CONCLUSIONS: Atypical and typical antipsychotic drug use were both strongly associated with raised risks, as were SSRIs. Tricyclic antidepressants were not associated with raised risks. The Arizona classification of risk of TdP was a poor predictor of likelihood of noncardiac drug-associated sudden death.
AIMS: To examine risks of sudden death in the community associated with drugs grouped by their risk of causing torsades de pointes (TdP) and to explore the risks for individual drugs. METHODS: Case-control study comparing prior drug intakes and morbidities, using the Arizona classification of drugs causing TdP. Participants included 1010 patients dying suddenly where post-mortem examination did not identify a clear cause of death, and 3030 matched living controls from primary care. RESULTS: Noncardiac drug risk was posed by antipsychotics and antidepressants. Significantly raised odds ratios (ORs) were found for takers of typical and atypical antipsychotics, ORs [95% confidence interval] 3.94 (2.05, 7.55) and 4.36 (2.54, 7.51), and of selective serotonin reuptake inhibitors [SSRIs] rather than tricyclic antidepressants, ORs 2.21 (1.61, 3.05) and 1.44 (0.96, 2.13). No significant risk was associated with other, noncardiac or psychiatric drugs, OR 1.09 (0.85, 1.41). Arizona classified drugs considered to raise risk of TdP were associated with raised risk of sudden death, as were those only weakly associated with TdP and not considered to pose a risk in normal use, ORs 2.08 (1.45, 3.00) and 1.74 (1.33, 2.28), respectively. CONCLUSIONS: Atypical and typical antipsychotic drug use were both strongly associated with raised risks, as were SSRIs. Tricyclic antidepressants were not associated with raised risks. The Arizona classification of risk of TdP was a poor predictor of likelihood of noncardiac drug-associated sudden death.
Authors: Ellyn M Johnson; Ellen Whyte; Benoit H Mulsant; Bruce G Pollock; Elizabeth Weber; Amy E Begley; Charles F Reynolds Journal: Am J Geriatr Psychiatry Date: 2006-09 Impact factor: 4.105
Authors: Anthony A Fossa; William Gorczyca; Todd Wisialowski; Adam Yasgar; Ellen Wang; Kimberly Crimin; Walter Volberg; Jun Zhou Journal: J Pharmacol Toxicol Methods Date: 2006-04-25 Impact factor: 1.950
Authors: Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart Journal: N Engl J Med Date: 2005-12-01 Impact factor: 91.245
Authors: Sudeep S Gill; Susan E Bronskill; Sharon-Lise T Normand; Geoffrey M Anderson; Kathy Sykora; Kelvin Lam; Chaim M Bell; Philip E Lee; Hadas D Fischer; Nathan Herrmann; Jerry H Gurwitz; Paula A Rochon Journal: Ann Intern Med Date: 2007-06-05 Impact factor: 25.391
Authors: R S Duncan; M J McPate; J M Ridley; Z Gao; A F James; D J Leishman; J L Leaney; H J Witchel; J C Hancox Journal: Biochem Pharmacol Date: 2007-05-03 Impact factor: 5.858
Authors: Charles E Leonard; Cristin P Freeman; Craig W Newcomb; Warren B Bilker; Stephen E Kimmel; Brian L Strom; Sean Hennessy Journal: J Clin Exp Cardiolog Date: 2013
Authors: Sabrina A Poole; Anna Pecoraro; Geetha Subramaniam; George Woody; Victoria L Vetter Journal: J Addict Med Date: 2016 Jan-Feb Impact factor: 3.702
Authors: A Biffi; F Rea; L Scotti; A Mugelli; E Lucenteforte; A Bettiol; A Chinellato; G Onder; C Vitale; N Agabiti; G Trifirò; G Roberto; G Corrao Journal: Eur J Clin Pharmacol Date: 2017-10-18 Impact factor: 2.953